LEADER 04945nam 2201609z- 450 001 9910557129403321 005 20210501 035 $a(CKB)5400000000040760 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68362 035 $a(oapen)doab68362 035 $a(EXLCZ)995400000000040760 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNovel Biomarkers in Alzheimer's Disease 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (442 p.) 311 08$a3-03943-903-0 311 08$a3-03943-904-9 330 $aAlzheimer's disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a critical need to establish biomarkers that can be used to detect AD in individuals before the onset of clinical signs and provide mitigating therapeutics. The aim of this Special Issue is to discuss the current knowledge as well as future perspectives on the role of biomarkers in the screening, diagnosis, treatment and follow-up of AD. 606 $aMedicine and Nursing$2bicssc 610 $a(18F)FDG 610 $aadipose tissue dysfunction 610 $aageing 610 $aaging 610 $aAlzheimer disease 610 $aAlzheimer's disease 610 $aAlzheimer's disease 610 $aAlzheimer's disease (AD) 610 $aamyloid 610 $aamyloid beta 610 $aAmyloid Beta 610 $aamyloid beta peptide 610 $aamyloid cascade hypothesis 610 $aantioxidant 610 $aApoE 610 $aAPOE 610 $aAPOE alleles 610 $aAPP mutations 610 $abacteria 610 $abehavioral and psychological symptoms of dementia (BPSD) 610 $abeta-amyloid 610 $abiofluids 610 $abiomarker 610 $abiomarkers 610 $ablood 610 $acardiovascular risk factors 610 $acarotenoids 610 $aCART analysis 610 $acerebrospinal fluid 610 $aclinical trials 610 $aClock 610 $aclock genes 610 $acognition 610 $acognitive decline 610 $aCOMT 610 $acytokines 610 $adementia 610 $adiabetes 610 $adiagnosis 610 $adiagnostic research 610 $adiagnostics 610 $adrug development 610 $aearly diagnosis 610 $aearly onset AD 610 $aEEG 610 $aendophenotypes 610 $aenergetic metabolism 610 $aepisodic memory 610 $aexosomes 610 $afamilial AD 610 $aflotillin 610 $agenetic variants 610 $agenetics of AD 610 $agermline mutations 610 $aglucose metabolism 610 $aglycolytic reserve 610 $ainflammation 610 $alate onset AD 610 $alysosomes dysfunction 610 $amembrane potential 610 $amessenger RNA 610 $ametabolomics 610 $amicroRNA 610 $amild cognitive impairment 610 $amitochondrial 610 $amitochondrial dysfunction 610 $amitochondrial spare respiratory capacity 610 $aMTHFR 610 $aMultiplex 610 $amultivariate analysis 610 $an/a 610 $aneurodegeneration 610 $aneurofilament light chain 610 $aneuroimaging 610 $aneuroinflammation 610 $aneuropsychiatry inventory scale (NPI) 610 $aneuropsychological assessment 610 $aneuropsychology 610 $aneurotropic microbes 610 $aNfL 610 $anutrition 610 $aobesity 610 $aolder adults 610 $aomega-3 fatty acids 610 $aperson-tailored 610 $aPET/CT 610 $aphonemic fluency 610 $aphosphorylated tau 610 $aphysical performance 610 $aprecision medicine 610 $aprognostics 610 $aPSEN1 610 $aPSEN2 610 $asemantic memory 610 $asemantic priming 610 $aSiMoA 610 $asoluble TREM2 610 $asubjective cognitive decline 610 $asynaptic biomarkers 610 $atau 610 $aTau 610 $aTMS 610 $atotal tau 610 $aType-3-Diabetes 610 $avirus 610 $avitamin E 615 7$aMedicine and Nursing 700 $aVilla$b Chiara$4edt$01280948 702 $aVilla$b Chiara$4oth 906 $aBOOK 912 $a9910557129403321 996 $aNovel Biomarkers in Alzheimer's Disease$93031265 997 $aUNINA